Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
132 results
  • A novel therapeutic paradigm for patients with extensive alopecia areata. [Review]
  • EOExpert Opin Biol Ther 2016; 16(8):1005-14
  • Renert-Yuval Y, Guttman-Yassky E
  • CONCLUSIONS: The translational revolution leading to improved therapeutic strategies has just begun for AA. These treatments are often associated with better safety and higher efficacy compared to currently used immune-suppressants. Different pathways might drive the inflammatory process in AA. Ongoing and future clinical trials utilizing narrow- targeted therapeutics will be able to better elucidate the role of each cytokine pathway in creating the AA disease phenotype.
  • Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma. [Review]
  • APAnn Pharmacother 2016; 50(5):416-22
  • Ploessl C, Pan A, … Lowe DK
  • CONCLUSIONS: Dinutuximab is the first anti-GD2 monoclonal antibody approved in combination with GM-CSF, IL-2, and RA for maintenance treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to first-line multiagent, multimodality therapy. Ongoing research will determine if dinutuximab could be used earlier in treatment, in nonresponders to initial therapies, in combination with chemotherapy, or in other cancers.
New Search Next